Pharmaceutical News

RSS

Perrigo's partner receives final approval for Epinastine HCl ophthalmic solution

Perrigo Company today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05%, a generic version of Elestat. Perrigo will commence shipment of the product immediately.

2 Nov 2011

ProPhase Labs introduces new Cold-EEZE Oral Spray

ProPhase Labs, makers of Cold-EEZE, a leader in over-the-counter (OTC) homeopathic cold remedies, continues to pioneer the category as they launch their first-ever Cold-EEZE Oral Spray. The new Oral Spray is formulated with zinc gluconate, the same effective active ingredient found in the best-selling, clinically proven and #1 pharmacist recommended Cold-EEZE lozenges.

1 Nov 2011

National lupus organizations urge NICE to recommend Benlysta for coverage

National lupus organizations in more than 28 countries, and individuals with lupus and their families around the world, are rallying to protect access to new treatments and the development of future therapies to treat lupus.

1 Nov 2011

Internet-based communication improves teenagers' use of topical acne therapy

Tech-savvy teens with acne used their medicine more frequently when they also took part in a web-based survey, a new study from Wake Forest Baptist Medical Center finds.

1 Nov 2011

LA BioMed's lead investigator hopes to bring PAH awareness this November

As the month of November kicks off PH Awareness Month, Dr. Ronald Oudiz - lead investigator at the Los Angeles Biomedical Research Institute (LA BioMed) - hopes to bring greater awareness to this disorder that has affected the lives of so many. Dr. Oudiz is a pioneer in this field, having received the 2011 Award for Excellence earlier this year from the Pulmonary Hypertension Association for his dedication to find new ways to treat this often fatal disease.

1 Nov 2011

Potential role for UV light exposure, vitamin D levels in chronic digestive conditions

New research points to a potential role for UV light exposure and vitamin D levels in chronic digestive conditions.

1 Nov 2011

Azantis introduces reduced glutathione and vitamin C liposomal products

Azantis launched today two innovative liposomal products: reduced glutathione and vitamin C. Both oral supplements are formulated in liposomal form to maximize absorption and to minimize side effects. Azantis, a leading phospholipid manufacturer, markets the liposomal products to resellers targeting the health care practitioner channel.

1 Nov 2011

Panel backs anthrax vaccine testing on children

An important panel of government advisers Friday recommended that the government should sponsor a controversial study to test the anthrax vaccine in children to see whether the inoculation would protect young Americans against a bioterrorist's attack.

31 Oct 2011

Cardinal Health launches Protexis Latex Blue surgical gloves with emollient coating

Cardinal Health today announced the launch of its new Protexis™ Latex Blue with Neu-Thera® sterile latex powder-free surgical gloves with emollient coating.

31 Oct 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

Avanir Pharmaceuticals, Inc. announced today that it has submitted an application to the European Medicines Agency seeking marketing authorization for NUEDEXTA (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect.

31 Oct 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.

31 Oct 2011

PPRT publishes study that evaluates pharmacist provision of clozapine

According to a study which evaluated alternative models for the delivery of clozapine services, published by the Pharmacy Practice Research Trust (PPRT), there is scope to review the team configurations needed to deliver community services in a cost-effective manner and to provide opportunities for improving the services provided to patients.

31 Oct 2011

GC-C agonists have potential to delay progression of colitis into colon cancer

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011 annual scientific meeting of the American College of Gastroenterology highlights the potential use of guanylate cyclase-C agonists to delay progression of colitis into colon cancer.

31 Oct 2011

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

31 Oct 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

FDA approves Pacira's EXPAREL for postsurgical pain management

Pacira Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved EXPAREL 1.3% for administration into the surgical site to produce postsurgical analgesia.

31 Oct 2011

BerGenBio commences preclinical development of BGB324 anti-cancer drug

BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.

31 Oct 2011

Hercules Pharma granted rights to license 22nd Century's X-22 smoking cessation aid

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that the company licensed Hercules Pharmaceuticals LLC, its wholly-owned pharmaceutical subsidiary, exclusive worldwide rights to X-22.

31 Oct 2011

Study examines link between hormonal forms of contraception and sexual functioning

Today's hormonal forms of birth control are vastly different from those used by earlier generations of women, both with lower levels of hormones and with different means of delivery (not just a pill), but many of the same problems related to women's pleasure remain.

31 Oct 2011

Pharmaceutical News

Perrigo's partner receives final approval for Epinastine HCl ophthalmic solution

ProPhase Labs introduces new Cold-EEZE Oral Spray

National lupus organizations urge NICE to recommend Benlysta for coverage

Internet-based communication improves teenagers' use of topical acne therapy

LA BioMed's lead investigator hopes to bring PAH awareness this November

Potential role for UV light exposure, vitamin D levels in chronic digestive conditions

Azantis introduces reduced glutathione and vitamin C liposomal products

Panel backs anthrax vaccine testing on children

Cardinal Health launches Protexis Latex Blue surgical gloves with emollient coating

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

New antibiotic regimes may increase infections after specific surgical procedures

PPRT publishes study that evaluates pharmacist provision of clozapine

GC-C agonists have potential to delay progression of colitis into colon cancer

Pacira's third quarter total revenues decrease to $4.0 million

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

FDA approves Pacira's EXPAREL for postsurgical pain management

BerGenBio commences preclinical development of BGB324 anti-cancer drug

Hercules Pharma granted rights to license 22nd Century's X-22 smoking cessation aid

Study examines link between hormonal forms of contraception and sexual functioning

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News